Microbial SCFAs for the Treatment of Type 1 Diabetes and Prevention of Kidney Fibrosis

My doctoral research investigated the impact of HAMSAB dietary supplementation on Type 1 Diabetes (T1D) immunotherapy and Kidney Fibrosis by modifying the gut microbiota and releasing specific microbial metabolites, including short-chain fatty acids (SCFAs). The study found that the HAMSAB diet's anti-inflammatory properties enhance the effects of anti-CD3 immunotherapy and protect against the development of T1D by regulating the gut microbiota and promoting immunoregulation. Additionally, the study highlighted the potential benefits of SCFAs in improving kidney function and mitigating inflammation in kidney disease, suggesting that SCFA-based diets could be a promising therapeutic approach for preventing CKD progression. These findings offer a widely acceptable, non-invasive, and highly accessible method for treating individuals with newly diagnosed or high-risk inflammatory and autoimmune diseases.